A Bad Hand: Random Chance May Play a Role in Cancer
February 29, 2016 – Erik Ness
Planting a Seed: Plant-Based Diets Prove Best for Patients and Survivors
February 29, 2016 – Melissa Silverberg
Brain Trust: Cutting-Edge Treatments for Glioblastoma on the Rise
March 01, 2016 – Arlene Weintraub
Single File: Living Alone With Cancer
March 01, 2016 – Theresa Sullivan Barger
Hold the Phone: Does Cell Phone Use Cause Cancer?
March 01, 2016 – Barbara Sadick
Star of TV's "The Little Couple" Shares What Having a Rare Cancer Taught Her
March 02, 2016 – Beth Fand Incollingo
Getting Warmer: Women Can Revive Sexual Function After Cancer
March 02, 2016 – Mark Hoffman, MD, and Rachel Hoffman, LMSW
On the Road to Recovery: Traveling for Cancer Treatment
March 07, 2016 – Andrew Smith
Currently Viewing
Medical Illustration: Novel Treatments for Glioblastoma
March 08, 2016 – Erin Moore
HPV Vaccine Uptake Low Among Boys
March 09, 2016 – Beth Fand Incollingo
A Cancer Survivor's Menu
March 10, 2016 – Melissa Silverberg
Facing a Fierce Opponent, and Gaining Ground
March 12, 2016 – Mike Hennessy, Sr.
What Causes Cancer? Three Main Culprits
March 21, 2016 – Debu Tripathy, MD
Men and Women Use Different Strategies to Choose Cancer Treatments
March 28, 2016 – Marilyn Fenichel
Heal: The Vital Role of Dogs in the Search for Cancer Cures
March 31, 2016 – Beth Fand Incollingo

Medical Illustration: Novel Treatments for Glioblastoma

Medical illustrations by Erin Moore explaining novel treatments for glioblastoma.
BY Erin Moore
PUBLISHED March 08, 2016

How Tumor-Treating Fields Work

Optune is a device worn on the head that delivers low-intensity electrical fields, known as tumor-treating fields, directly to brain tumors.
Optune is a device worn on the head that delivers low-intensity electrical fields, known as tumor-treating fields, directly to brain tumors.

It’s a new technology never used before in cancer.

Optune works by disrupting the ability of cancer cells, specifically, to divide and multiply. The fields mainly affect cancer cells because they divide much more frequently than normal cells. If a cell isn’t dividing, an electrical field will surround but not pierce it. However, during division, cells are polarized, making it possible for the current to cut through them, damaging their DNA and destroying them.

The dividing cells can only be pierced if they are lined up with the electrical current, and this doesn’t always happen immediately with Optune, since cells may rotate a bit, moving out of range, during the division process. Patients wear the devices 18 hours a day so they’ll have the best chances of targeting the most cells.
How Tumor-Treating Fields Work

Rintega (rindopepimut)

Glioblastomas are difficult to treat because they contain an enormous variety of cell types. There is, however, a growth factor mutation, EGFRvIII, that is seen in about 30 percent of glioblastomas, but not in healthy cells. The Rintega (rindopepimut) vaccine targets this mutated protein, teaching the immune system to recognize and attack any cells that contain it.

The vaccine is made for each patient by combining tumor cells with synthetic peptides designed to stimulate an immune response to EGFRvIII.

Also being developed is a different approach (ICT-107) that harvests a patient’s immune, or “dendritic,” cells and exposes them to antigens that are often expressed in glioblastoma. Back in the body, these treated cells draw attention to the cancer-causing antigens, stimulating the immune system to fight them.

CAR T-cells

CAR T-cells
Chimeric antigen receptor T cells (CAR T cells) are immune cells taken from patients, genetically engineered to include a viral vector designed to seek mutated cells, and reinfused.

In the body, the engineered immune cells bind to mutated EGFRvIII that sits on the outsides of cancer cells. This either prevents EGFRvIII from signaling surrounding cancer cells to grow, or stimulates immune cells to secrete cytokines that kill the cancer cells.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Brain Cancer CURE discussion group.

Related Articles


Sign In

Not a member? Sign up now!

Sign Up

Are you a member? Please Log In